Science has gained deep understanding of T-regulatory (Treg) cells and how to use them for therapeutical purposes in auto-immune diseases. This is what three leading research institutes in Europe showed in a peer-reviewed article in Frontiers in Immunology, the world’s fifth-most cited immunology journal. Contributors were PolTREG S.A. CEO Prof. Piotr Trzonkowski, and researchers from the groups of Prof. Ye Htun Oo at the University of Birmingham, Prof. Anke Fuchs from the Technical University of Dresden (Technische Universität Dresden), and Prof. Natalia Maria Marek- Trzonkowska from the International Centre for Cancer Vaccine Science, University of Gdansk. PolTREG is developing a comprehensive and exciting pipeline of new therapeutics, tapping into the full potential that Treg cells offer as disease-modifying treatment for conditions such as Type-1 Diabetes and Multiple Sclerosis, including next-generation engineered Treg cells.